Pictet & Cie Europe SA Has $3.65 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Pictet & Cie Europe SA lifted its position in Illumina, Inc. (NASDAQ:ILMN) by 34.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,050 shares of the life sciences company’s stock after acquiring an additional 5,400 shares during the period. Pictet & Cie Europe SA’s holdings in Illumina were worth $3,653,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Advisory Services Network LLC purchased a new position in Illumina during the first quarter worth approximately $117,000. Penserra Capital Management LLC lifted its position in Illumina by 13.0% during the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after buying an additional 102 shares in the last quarter. Paradigm Asset Management Co. LLC lifted its position in Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares in the last quarter. Patten Group Inc. lifted its position in Illumina by 2.7% during the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. lifted its position in Illumina by 11.3% during the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after buying an additional 100 shares in the last quarter. 93.34% of the stock is currently owned by hedge funds and other institutional investors.

Illumina, Inc. (NASDAQ ILMN) opened at 210.72 on Friday. The firm has a market capitalization of $30.77 billion, a PE ratio of 42.28 and a beta of 0.81. The company’s 50-day moving average price is $197.88 and its 200 day moving average price is $180.42. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $214.34.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. The business had revenue of $662.00 million for the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.86 earnings per share. On average, equities analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current year.

A number of brokerages recently commented on ILMN. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price objective on the stock in a research report on Tuesday, May 23rd. First Analysis upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price objective on the stock in a research report on Wednesday, August 2nd. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Barclays PLC reiterated an “equal weight” rating and set a $150.00 price objective on shares of Illumina in a research report on Wednesday, August 9th. Finally, Canaccord Genuity restated a “hold” rating and issued a $170.00 target price on shares of Illumina in a research report on Wednesday, July 26th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company. Illumina has an average rating of “Hold” and a consensus price target of $181.76.

COPYRIGHT VIOLATION WARNING: “Pictet & Cie Europe SA Has $3.65 Million Stake in Illumina, Inc. (NASDAQ:ILMN)” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://ledgergazette.com/2017/09/17/pictet-cie-europe-sa-increases-position-in-illumina-inc-ilmn.html.

In other news, SVP Charles Dadswell sold 145 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $174.24, for a total transaction of $25,264.80. Following the sale, the senior vice president now directly owns 10,646 shares of the company’s stock, valued at $1,854,959.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Michel Bouchard sold 616 shares of the stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,200.00. Following the sale, the chief accounting officer now directly owns 15,161 shares in the company, valued at $3,032,200. The disclosure for this sale can be found here. Insiders have sold 195,434 shares of company stock worth $37,480,647 over the last ninety days. Insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply